Table 2.
Estimated mean PANSS score over the 18 months of the CATIE study for each of the 9 treatment regimes and 95% confidence intervals. The columns entitled Complete Case report the number of people (N) contributing information to estimating the mean response for each regime, the estimated mean response and corresponding 95% CI. The columns entitled Multiple Imputation report the number of people (N) averaged over 25 imputations contributing information to estimating the mean response for each regime as well as the estimated mean response and 95% CI.
| Complete Case | Multiple Imputation | |||
|---|---|---|---|---|
| Treatment Regimes | N | Mean [95% CI] | N | Mean [95% CI] |
| Olanzapine, if nonresponder, then Quetiapine | 101 | 62.41 [60.05, 64.76] | 186.3 | 65.99 [63.97, 68.00] |
| Olanzapine, if nonresponder, then Risperidone Olanzapine, if nonresponder |
103 | 62.93 [60.46, 65.40] | 186.8 | 66.08 [64.09, 68.07] |
| due to efficacy, then clozapine, due to tolerance, then ziprasidone |
109 | 63.21 [60.77, 65.65] | 208.9 | 66.96 [65.04, 68.87] |
| Quetiapine, if nonresponder, then Olanzapine | 56 | 64.09 [60.66,67.51] | 145.4 | 68.86 [66.57,71.15] |
| Quetiapine, if nonresponder, then Risperidone Quetiapine, if nonresponder |
61 | 65.12 [62.01,68.23] | 146.1 | 69.32 [67.06,71.57] |
| due to efficacy, then clozapine, due to tolerance, then ziprasidone |
64 | 65.75 [62.62, 68.89] | 169.5 | 70.25 [67.92, 72.57] |
| Risperidone, if nonresponder, then Olanzapine | 83 | 66.67 [63.80, 69.54] | 167.5 | 69.14 [66.92,71.35] |
| Risperidone, if nonresponder, then Quetiapine Risperidone, if nonresponder |
79 | 65.49 [62.55, 68.44] | 168.8 | 69.51 [67.31,71.71] |
| due to efficacy, then clozapine, due to tolerance, then ziprasidone |
83 | 66.32 [63.50,69.14] | 186.7 | 70.29 [68.08, 72.49] |